Overview

Data as of February 20, 2019 10:29 pm EST

Press Releases

Summary Toggle Phase 2 Results for Madrigal’s MGL-3196 in Non-Alcoholic Steatohepatitis (NASH) Presented during Presidential Plenary Clinical Session of The Liver Meeting® 2018

November 12, 2018

-- Statistically significantly more NASH resolution in MGL-3196 as compared with placebo in a Phase 2 clinical trial support MGL-3196 as a first- and potentially best-in class thyroid hormone receptor (THR) β-selective agonist for treating patients with NASH --The fact that MGL-3196 lowers LDL
Summary Toggle Madrigal Pharmaceuticals Reports 2018 Third Quarter Financial Results and Highlights Upcoming Clinical Events

November 06, 2018

CONSHOHOCKEN, Pa. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2018 financial results and described upcoming clinical events: “Madrigal made important progress thus far in 2018 to advance the development of MGL-3196, through
Summary Toggle Madrigal Pharmaceuticals Reports 2018 Second Quarter Financial Results and Reviews Key Clinical Achievements

August 07, 2018

Madrigal’s MGL-3196 NASH abstract selected for oral presentation in the presidential plenary clinical session of The Liver Meeting® 2018 during the American Association for the Study of Liver Diseases 2018 Annual Meeting CONSHOHOCKEN, Pa. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Madrigal

Filing date	Form	Description	Filing Group
May 31, 2002	REGDEX	REGDEX	Other
October 07, 2002	REGDEX	REGDEX	Other
April 21, 2003	REGDEX/A	REGDEX/A	Other